Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells

PURPOSE: Metformin, widely used as antidiabetic drug, showed antitumoral effects expecially in combination with chemotherapy. Our group recently has demonstrated that metformin and gefitinib are synergistic in LKB1-wild-type NSCLC cells. In these models, metformin as single agent induced an activati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Della Corte, Carminia Maria, Ciaramella, Vincenza, Mauro, Concetta Di, Castellone, Maria Domenica, Papaccio, Federica, Fasano, Morena, Sasso, Ferdinando Carlo, Martinelli, Erika, Troiani, Teresa, De Vita, Ferdinando, Orditura, Michele, Bianco, Roberto, Ciardiello, Fortunato, Morgillo, Floriana
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4826204/
https://ncbi.nlm.nih.gov/pubmed/26673006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6559
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados